AR070232A1 - Derivados de (beta)-aminoacidos - Google Patents
Derivados de (beta)-aminoacidosInfo
- Publication number
- AR070232A1 AR070232A1 ARP090100201A ARP090100201A AR070232A1 AR 070232 A1 AR070232 A1 AR 070232A1 AR P090100201 A ARP090100201 A AR P090100201A AR P090100201 A ARP090100201 A AR P090100201A AR 070232 A1 AR070232 A1 AR 070232A1
- Authority
- AR
- Argentina
- Prior art keywords
- cr9r10
- propionamide
- dihydro
- oxo
- phenyl
- Prior art date
Links
- -1 1 -Oxo-1,3-dihydro-isoindol-2-yl Chemical group 0.000 abstract 6
- 101100134929 Gallus gallus COR9 gene Proteins 0.000 abstract 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 4
- 229940080818 propionamide Drugs 0.000 abstract 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 235000010290 biphenyl Nutrition 0.000 abstract 2
- 239000004305 biphenyl Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 abstract 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 abstract 1
- APRATTNDLORJFG-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)-n-pyridin-2-ylpropanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=CC=N1 APRATTNDLORJFG-UHFFFAOYSA-N 0.000 abstract 1
- RMUULXHVYNHZBF-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-n-(5-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=C(C)C=N1 RMUULXHVYNHZBF-UHFFFAOYSA-N 0.000 abstract 1
- OEJXYAKMUUFPMI-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-n-(6-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=CC(C)=N1 OEJXYAKMUUFPMI-UHFFFAOYSA-N 0.000 abstract 1
- SBVFNYIOAWKDSB-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)-n-(1,3-thiazol-2-yl)-3-(3,4,5-trimethoxyphenyl)propanamide Chemical compound COC1=C(OC)C(OC)=CC(C(CC(=O)NC=2SC=CN=2)N2C(C3=CC=CC=C3C2)=O)=C1 SBVFNYIOAWKDSB-UHFFFAOYSA-N 0.000 abstract 1
- IPSFXCHUNUDSKS-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)-n-pyridin-2-yl-3-thiophen-2-ylpropanamide Chemical compound C=1C=CC=NC=1NC(=O)CC(N1C(C2=CC=CC=C2C1)=O)C1=CC=CS1 IPSFXCHUNUDSKS-UHFFFAOYSA-N 0.000 abstract 1
- XRUMTIMHZVQDQA-UHFFFAOYSA-N 3-(4-methoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)-n-pyridin-2-ylpropanamide Chemical compound C1=CC(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=CC=N1 XRUMTIMHZVQDQA-UHFFFAOYSA-N 0.000 abstract 1
- ITRSBXAOJQVEOW-UHFFFAOYSA-N 3-(4-methoxyphenyl)-n-(4-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=CC(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC(C)=CC=N1 ITRSBXAOJQVEOW-UHFFFAOYSA-N 0.000 abstract 1
- QXIJITNYCCMZDI-UHFFFAOYSA-N 3-(4-methoxyphenyl)-n-(5-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=CC(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=C(C)C=N1 QXIJITNYCCMZDI-UHFFFAOYSA-N 0.000 abstract 1
- PMYSKYMHOVWMAB-UHFFFAOYSA-N 3-(4-methoxyphenyl)-n-(6-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=CC(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=CC(C)=N1 PMYSKYMHOVWMAB-UHFFFAOYSA-N 0.000 abstract 1
- 102000030595 Glucokinase Human genes 0.000 abstract 1
- 108010021582 Glucokinase Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- IBRUVOZFXCYUPN-UHFFFAOYSA-N n-(5-bromopyridin-2-yl)-3-(3,4-dimethoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=C(Br)C=N1 IBRUVOZFXCYUPN-UHFFFAOYSA-N 0.000 abstract 1
- BPWWAPBGDABIHH-UHFFFAOYSA-N n-(5-bromopyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)-3-(3,4,5-trimethoxyphenyl)propanamide Chemical compound COC1=C(OC)C(OC)=CC(C(CC(=O)NC=2N=CC(Br)=CC=2)N2C(C3=CC=CC=C3C2)=O)=C1 BPWWAPBGDABIHH-UHFFFAOYSA-N 0.000 abstract 1
- KTMPTXPTUBHTDC-UHFFFAOYSA-N n-(5-bromopyridin-2-yl)-3-(4-methylphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=CC(C)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=C(Br)C=N1 KTMPTXPTUBHTDC-UHFFFAOYSA-N 0.000 abstract 1
- PQFKHILISYWWMV-UHFFFAOYSA-N n-(5-chloropyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)-3-(3,4,5-trimethoxyphenyl)propanamide Chemical compound COC1=C(OC)C(OC)=CC(C(CC(=O)NC=2N=CC(Cl)=CC=2)N2C(C3=CC=CC=C3C2)=O)=C1 PQFKHILISYWWMV-UHFFFAOYSA-N 0.000 abstract 1
- HQANKEHGKYKJBR-UHFFFAOYSA-N n-(5-chloropyridin-2-yl)-3-(4-fluorophenyl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=CC(F)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CC(=O)NC1=CC=C(Cl)C=N1 HQANKEHGKYKJBR-UHFFFAOYSA-N 0.000 abstract 1
- CYEJTXYXGQXFTD-UHFFFAOYSA-N n-(5-methylpyridin-2-yl)-3-(3-oxo-1h-isoindol-2-yl)-3-(3,4,5-trimethoxyphenyl)propanamide Chemical compound COC1=C(OC)C(OC)=CC(C(CC(=O)NC=2N=CC(C)=CC=2)N2C(C3=CC=CC=C3C2)=O)=C1 CYEJTXYXGQXFTD-UHFFFAOYSA-N 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08001305 | 2008-01-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070232A1 true AR070232A1 (es) | 2010-03-25 |
Family
ID=40386192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100201A AR070232A1 (es) | 2008-01-24 | 2009-01-23 | Derivados de (beta)-aminoacidos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8431602B2 (enExample) |
| EP (1) | EP2231640B1 (enExample) |
| JP (1) | JP5623914B2 (enExample) |
| KR (1) | KR20100110367A (enExample) |
| CN (1) | CN101925596B (enExample) |
| AR (1) | AR070232A1 (enExample) |
| AU (1) | AU2008348817B2 (enExample) |
| BR (1) | BRPI0821827A2 (enExample) |
| CA (1) | CA2712998A1 (enExample) |
| CY (1) | CY1112919T1 (enExample) |
| DK (1) | DK2231640T3 (enExample) |
| EA (1) | EA017775B1 (enExample) |
| ES (1) | ES2388475T3 (enExample) |
| HR (1) | HRP20120510T1 (enExample) |
| IL (1) | IL206904A0 (enExample) |
| MX (1) | MX2010007926A (enExample) |
| PL (1) | PL2231640T3 (enExample) |
| PT (1) | PT2231640E (enExample) |
| SI (1) | SI2231640T1 (enExample) |
| WO (1) | WO2009092432A1 (enExample) |
| ZA (1) | ZA201006002B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| IL291017B2 (en) | 2015-10-21 | 2023-11-01 | Otsuka Pharma Co Ltd | Benzolactam compounds as protein kinase inhibitors |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| WO2024229228A2 (en) * | 2023-05-02 | 2024-11-07 | The Rockefeller University | 1-oxoisoindolin-2-yl amide activators of vcp and derivatives thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US6482951B2 (en) * | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
| BR0315316A (pt) | 2002-10-15 | 2005-08-16 | Celgene Corp | Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit |
| CA2511843C (en) * | 2002-12-30 | 2012-04-24 | Celgene Corporation | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses |
| AU2005302523A1 (en) * | 2004-10-28 | 2006-05-11 | Celgene Corporation | Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury |
| JP5386350B2 (ja) * | 2006-05-31 | 2014-01-15 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体 |
-
2008
- 2008-12-23 CN CN200880125427.7A patent/CN101925596B/zh not_active Expired - Fee Related
- 2008-12-23 WO PCT/EP2008/011099 patent/WO2009092432A1/en not_active Ceased
- 2008-12-23 BR BRPI0821827-7A patent/BRPI0821827A2/pt not_active IP Right Cessation
- 2008-12-23 JP JP2010543387A patent/JP5623914B2/ja not_active Expired - Fee Related
- 2008-12-23 PL PL08871581T patent/PL2231640T3/pl unknown
- 2008-12-23 EA EA201001174A patent/EA017775B1/ru not_active IP Right Cessation
- 2008-12-23 KR KR1020107018265A patent/KR20100110367A/ko not_active Ceased
- 2008-12-23 CA CA2712998A patent/CA2712998A1/en not_active Abandoned
- 2008-12-23 EP EP08871581A patent/EP2231640B1/en not_active Not-in-force
- 2008-12-23 ES ES08871581T patent/ES2388475T3/es active Active
- 2008-12-23 HR HRP20120510AT patent/HRP20120510T1/hr unknown
- 2008-12-23 PT PT08871581T patent/PT2231640E/pt unknown
- 2008-12-23 AU AU2008348817A patent/AU2008348817B2/en not_active Ceased
- 2008-12-23 MX MX2010007926A patent/MX2010007926A/es active IP Right Grant
- 2008-12-23 US US12/864,348 patent/US8431602B2/en not_active Expired - Fee Related
- 2008-12-23 SI SI200830736T patent/SI2231640T1/sl unknown
- 2008-12-23 DK DK08871581.8T patent/DK2231640T3/da active
-
2009
- 2009-01-23 AR ARP090100201A patent/AR070232A1/es unknown
-
2010
- 2010-07-08 IL IL206904A patent/IL206904A0/en unknown
- 2010-08-23 ZA ZA2010/06002A patent/ZA201006002B/en unknown
-
2012
- 2012-07-24 CY CY20121100656T patent/CY1112919T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011510029A (ja) | 2011-03-31 |
| KR20100110367A (ko) | 2010-10-12 |
| IL206904A0 (en) | 2010-12-30 |
| WO2009092432A1 (en) | 2009-07-30 |
| ZA201006002B (en) | 2011-04-28 |
| MX2010007926A (es) | 2010-08-09 |
| EP2231640B1 (en) | 2012-06-06 |
| ES2388475T3 (es) | 2012-10-15 |
| HRP20120510T1 (hr) | 2012-07-31 |
| PT2231640E (pt) | 2012-08-23 |
| EP2231640A1 (en) | 2010-09-29 |
| CN101925596B (zh) | 2014-05-28 |
| CN101925596A (zh) | 2010-12-22 |
| JP5623914B2 (ja) | 2014-11-12 |
| BRPI0821827A2 (pt) | 2015-06-16 |
| SI2231640T1 (sl) | 2012-09-28 |
| CY1112919T1 (el) | 2016-04-13 |
| AU2008348817A1 (en) | 2009-07-30 |
| US20100331346A1 (en) | 2010-12-30 |
| AU2008348817B2 (en) | 2011-12-15 |
| EA017775B1 (ru) | 2013-03-29 |
| US8431602B2 (en) | 2013-04-30 |
| CA2712998A1 (en) | 2009-07-30 |
| PL2231640T3 (pl) | 2012-09-28 |
| EA201001174A1 (ru) | 2011-02-28 |
| DK2231640T3 (da) | 2012-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070232A1 (es) | Derivados de (beta)-aminoacidos | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| AR095312A1 (es) | Compuestos de biarilamida como inhibidores de cinasa | |
| AR085637A1 (es) | Derivados de pirido[2,3-b]pirazina | |
| AR067506A1 (es) | Derivados de quinazolinamida | |
| AR068749A1 (es) | Derivados de n-(pirazol-3-il)-benzamida | |
| AR056979A1 (es) | Derivados de dihidrobenzofuranos y usos de los mismos | |
| AR079690A1 (es) | Derivados heterociclicos de pirrol[2,3-b]piridina, composiciones farmaceuticas que los contienen, procedimiento para prepararlos y uso de los mismos como agentes anticancer. | |
| AR061735A1 (es) | Derivados de indazol, composiciones farmaceuticas y uso de los mismos | |
| AR110421A1 (es) | Derivados de pirazol como inhibidores de malt1 | |
| WO2015121812A1 (en) | Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use | |
| AR071112A1 (es) | Derivados de benzopirano y benzoxepina inhibidores de quinasaspi3k, utiles como agentes anticancer,y composiciones farmaceuticas que los contienen. | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR089134A1 (es) | Arilos y heteroarilos biciclicos inhibidores de los canales de sodio | |
| AR066225A1 (es) | Derivados de quinolina - carboxamida en calidad de antagonistas de p2y12 | |
| AR082696A1 (es) | Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras | |
| AR035777A1 (es) | Derivados de pirazol sustituidos, procesos para su preparacion, composiciones farmaceuticas que los contienen, y su uso en medicina | |
| AR068730A1 (es) | Compuestos de diaril 1,2,4-oxadiazol,composiciones farmaceuticas que los contienen,proceso de preparacion y uso de los mismos como agentes inmunosupresores en el tratamiento de enfermedades autoinmunes y/o inflamatorias cronicas. | |
| AR107928A1 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| AR089944A1 (es) | Derivados de tetrahidro-quinazolinona | |
| PE20141351A1 (es) | Triazolopiridinas | |
| AR092211A1 (es) | Derivados de hidropirrolopirrol | |
| AR072860A1 (es) | Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina | |
| AR081828A1 (es) | Compuestos de biguanida y su uso para el tratamiento del cancer | |
| AR075531A1 (es) | Derivados de piperazin-ciclopropil benzamidas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central, tales como alzheimer y esquizofrenia, entre otros |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure | ||
| FB | Suspension of granting procedure |